Myelodysplastic syndromes (MDS) with a deletion 5q display a specific immunophenotypic profile

被引：0
|
作者：
Oelschlaegel, U. [1 ]
Westers, T. M. [2 ]
Mohr, B. [1 ]
Parmentier, S. [1 ]
Sockel, K. [1 ]
Bornhaeuser, M. [1 ]
Van de Loosdrecht, A. A. [2 ]
Platzbecker, U. [1 ]
机构：
[1] Univ Hosp Dresden, Med Clin & Policlin 1, Dresden, Germany
[2] Vrije Univ Amsterdam Med Ctr, Canc Ctr Amsterdam, Dept Hematol, Amsterdam, Netherlands
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70106-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-057
引用
收藏
页码：S47 / S48
页数：2
相关论文
共 50 条
  • [21] CURRENT TREATMENT OF MDS WITH DELETION 5Q
    Sekeres, M.
    LEUKEMIA RESEARCH, 2023, 128
  • [22] Variability in the size of del(5q) and its clinical implication in myelodysplastic syndromes (MDS)
    Zemanova, Zuzana
    Sejgunovova, Nikola
    Svobodova, Karla
    Lhotska, Halka
    Vidlakova, Denisa
    Aghova, Tatiana
    Lizcova, Libuse
    Izakova, Silvia
    Mendlikova, Iveta
    Ransdorfova, Sarka
    Hodanova, Lucie
    Pavlistova, Lenka
    Belickova, Monika
    Brezinova, Jana
    Cermak, Jaroslav
    Stopka, Tomas
    Jonasova, Anna
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 559 - 560
  • [23] Variability in the extent of del(5q) and its clinical implication in myelodysplastic syndromes (MDS).
    Zemanova, Zuzana
    Brezinova, Jana
    Svobodova, Karla
    Lhotska, Halka
    Izakova, Silvia
    Sarova, Iveta
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Chromosome 5q deletion in myelodysplastic syndrome
    Dwilewicz-Trojaczek, J.
    Madry, K.
    Paluszewska, M.
    Wiater, E.
    Szmigielska, A.
    Mital, A.
    Sledziowski, P.
    Salamanczuk, Z.
    Sikorska, A.
    Helbig, G.
    Wasilewska, E.
    Biedron, M.
    Calbecka, M.
    Jedrzejczak, W. W.
    LEUKEMIA RESEARCH, 2007, 31 : S91 - S91
  • [25] SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
    Talati, Chetasi
    Sallman, David
    List, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10): : 629 - 635
  • [26] Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
    Chesnais, Virginie
    Renneville, Aline
    Toma, Andrea
    Lambert, Jerome
    Passet, Marie
    Dumont, Florent
    Chevret, Sylvie
    Lejeune, Julie
    Raimbault, Anna
    Stamatoullas, Aspasia
    Rose, Christian
    Beyne-Rauzy, Odile
    Delaunay, Jacques
    Solary, Eric
    Fenaux, Pierre
    Dreyfus, Francois
    Preudhomme, Claude
    Kosmider, Olivier
    Fontenay, Michaela
    BLOOD, 2016, 127 (06) : 749 - 760
  • [27] USE OF GENOMIC BIOMARKERS RESPONSE PREDICTORS IN MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH 5Q DELETION
    Alarcon-Payer, C.
    Jimenez Morales, A.
    Badiola Gonzalez, J.
    Cornejo Calvo, M.
    Bernal Sanchez, M.
    Jurado Chacon, M.
    Hernandez Mohedo, F.
    HAEMATOLOGICA, 2018, 103 : 179 - 180
  • [28] The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes
    Melchert, Magda
    Kale, Vishakha
    List, Alan
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 123 - 129
  • [29] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [30] Efficacy of lenalidomide for treatment of anemia in secondary myelodysplastic syndrome (MDS) with chromosome 5q deletion
    Mintzer, David Michael
    Billet, Shira N.
    BLOOD, 2007, 110 (11) : 226B - 226B
12345